Drug intelligence / Profile preview

YT002

Development stage: Preclinical
Lead developer: Excyte Biopharma
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YT002 is a preclinical-stage trispecific antibody being developed by Excyte Biopharma for the treatment of solid tumors. As a trispecific therapeutic, it is engineered to simultaneously bind three different antigens or epitopes, potentially allowing for multi-pathway inhibition or enhanced immune cell recruitment to the tumor microenvironment. The specific molecular targets of YT002 have not been publicly disclosed by Excyte Biopharma. The drug is part of a pipeline focused on multi-specific antibodies designed for high-yield production, long half-lives, and low systemic toxicity.

Beyond the preview

Go deeper on YT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YT002.

Explore the full profile